SGHT — Sight Sciences Inc
NASDAQ · Healthcare · Medical Devices
$8.64
+$0.45 (+5.49%)
Sight Sciences Inc (SGHT) is a medical devices company listed on NASDAQ. It is led by Paul Badawi, based in 4040 Campbell Avenue, Menlo Park, CA, United States, 94025, with about 186 employees. Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest reported SGHT revenue for 2025-09-30 was $19.9M. Net income was -$34.3M. Revenue was up 1.7% from 2025-06-30 to 2025-09-30. SGHT currently screens at market cap $273.1M.
Use this SGHT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SGHT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SGHT SEC filings page. Lician reads the product cache first so this HTML stays unique to Sight Sciences Inc even when a live quote feed is slow.
About Sight Sciences Inc
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
SGHT Key Statistics
Market Cap
$273.14M
Volume
117,533
Previous Close
$8.32
Day Range
$8.18 – $8.44
P/B Ratio
5.07
EPS
-$1.03
Revenue
$79.87M
Net Income
-$51.51M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-1.5%
Profit Margin
-64.5%
Employees
186
SGHT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $79.87M | $81.06M | $71.33M | $48.96M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$51.51M | -$55.55M | -$86.24M | -$62.96M |
| EPS (Diluted) | -$1.03 | -$1.14 | -$1.80 | -$2.36 |
Total Assets
$142.84M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$120.36M
Operating Cash Flow
-$22.35M
Free Cash Flow
$0.00
Sight Sciences Inc Company Information
- Co-Founder, President, CEO & Director
- Paul Badawi
- Headquarters
- 4040 Campbell Avenue, Menlo Park, CA, United States, 94025
- Website
- www.sightsciences.com
- Phone
- 877 266 1144
- IPO / Founded
- 2021-07-15
- Sector
- Healthcare
- Industry
- Medical Devices